Breaking News

Tweet TWEET

Fibrocell Science to Present at Jefferies 2014 Global Healthcare Conference

  Fibrocell Science to Present at Jefferies 2014 Global Healthcare Conference  Jefferies 2014 Global Healthcare Conference  Business Wire  EXTON, Pa. -- May 29, 2014  Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer, and Greg Weaver, senior vice president and chief financial officer, ofFibrocell Science will present at the Jefferies 2014 Global Healthcare Conference at 3 p.m. EDT on Thursday, June 5, 2014, in New York City. Mr. Pernock and Mr. Weaver will discuss the company’s autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE:XON) to develop genetically-modified personalized biologics.  A live webcast of the presentation will be available on Fibrocell's website at http://www.fibrocellscience.com/investors/events-and-presentations/. The presentation will be archived on the company's website and available for 90 days.  About Fibrocell Science, Inc.  Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs. Based on its proprietary autologous fibroblast technology, Fibrocell is pursuing breakthrough medical applications of azficel-T for restrictive burn scarring and vocal cord scarring. The company’s collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, includes using genetically-modified fibroblasts for treating orphan skin diseases for which there are no currently approved products. For additional information, visit www.fibrocellscience.com.  Contact:  Corporate: Fibrocell Science, Inc. Gregory Weaver, +1 484-713-6000 Senior Vice President and Chief Financial Officer gweaver@fibrocellscience.com or Investor Relations: S.A. Noonan Communications, LLC Susan Noonan, 212-966-3650 susan@sanoonan.com  
Press spacebar to pause and continue. Press esc to stop.